Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Simona, Coco"'
Autor:
Sara Stigliani, Claudia Massarotti, Simona Coco, Guglielmo Mantica, Nataniele Piol, Bruno Spina, Elena Maccarini, Monica Colombo, Paola Anserini, Paola Scaruffi
Publikováno v:
The World Journal of Men's Health, Vol 41, Iss 4, Pp 969-973 (2023)
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 that has been spreading worldwide since December 2019. Viral entry into cells requires expression of both angiotensin-converting enzyme 2 (ACE2) and transmembrane protease
Externí odkaz:
https://doaj.org/article/14da4faeeb9a4e9286ceef280c95eb89
Autor:
Francesca Parisi, Giuseppa De Luca, Manuela Mosconi, Sonia Lastraioli, Chiara Dellepiane, Giovanni Rossi, Silvia Puglisi, Elisa Bennicelli, Giulia Barletta, Lodovica Zullo, Sara Santamaria, Marco Mora, Alberto Ballestrero, Fabrizio Montecucco, Andrea Bellodi, Lucia Del Mastro, Matteo Lambertini, Emanuela Barisione, Giuseppe Cittadini, Elena Tagliabue, Francesco Spagnolo, Marco Tagliamento, Simona Coco, Mariella Dono, Carlo Genova
Publikováno v:
Cancer Treatment and Research Communications, Vol 41, Iss , Pp 100839- (2024)
Background: Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process is often time-consuming and patients’ conditions might worsen while molecular analyses are processed.Our primary aim was to eva
Externí odkaz:
https://doaj.org/article/05ed2fe522d542a88e96e9b6c039d13b
Autor:
Giacomo Vallome, Iacopo Cafaro, Annarita Bottini, Chiara Dellepiane, Giovanni Rossi, Elisa Bennicelli, Francesca Parisi, Lodovica Zullo, Marco Tagliamento, Alberto Ballestrero, Emanuela Barisione, Ines Maria Grazia Piroddi, Fabrizio Montecucco, Federico Carbone, Paolo Pronzato, Matteo Lambertini, Francesco Spagnolo, Giulia Barletta, Lucrezia Barcellini, Michele Ferrante, Simone Nardin, Simona Coco, Silvia Marconi, Linda Zinoli, Paolo Moscatelli, Eleonora Arboscello, Lucia Del Mastro, Andrea Bellodi, Carlo Genova
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e21177- (2023)
Background: Lung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options and outcomes. This study aimed to investigate the clinical and molecular
Externí odkaz:
https://doaj.org/article/46d754b3a8b547b388883040cd0d56ad
Autor:
Carlo Genova, Chiara Dellepiane, Paolo Carrega, Sara Sommariva, Guido Ferlazzo, Paolo Pronzato, Rosaria Gangemi, Gilberto Filaci, Simona Coco, Michela Croce
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lympho
Externí odkaz:
https://doaj.org/article/fdf9dff0eeab48d6bc67db88fdefbeb5
Autor:
Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Vincenzo Fontana, Silvia Marconi, Michela Croce, Maria Giovanna Dal Bello, Chiara Dellepiane, Marco Tagliamento, Maria Chiara Ciferri, Lodovica Zullo, Alessandro Fedeli, Angela Alama, Katia Cortese, Chiara Gentili, Eugenia Cella, Giorgia Anselmi, Marco Mora, Giulia Barletta, Erika Rijavec, Francesco Grossi, Paolo Pronzato, Simona Coco
Publikováno v:
Cells, Vol 12, Iss 6, p 832 (2023)
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints
Externí odkaz:
https://doaj.org/article/1ae01a3f739d4d27868c612a121bdfb1
Autor:
Delfina Costa, Roberta Venè, Simona Coco, Luca Longo, Francesca Tosetti, Stefano Scabini, Luca Mastracci, Federica Grillo, Alessandro Poggi, Roberto Benelli
Publikováno v:
Cells, Vol 12, Iss 4, p 664 (2023)
The p38 inhibitor SB202190 is a necessary component of the medium used for normal colorectal mucosa cultures. Sato et al. suggested that the primary activity of SB202190 may be EGFR signaling stabilization, causing an increased phosphorylation of Erk
Externí odkaz:
https://doaj.org/article/249b59f0bf524e23ae11bca2225a796d
Autor:
Mariella Dono, Giuseppa De Luca, Sonia Lastraioli, Giorgia Anselmi, Maria Giovanna Dal Bello, Simona Coco, Irene Vanni, Francesco Grossi, Antonella Vigani, Carlo Genova, Manlio Ferrarini, Jean Louis Ravetti, Simona Zupo
Publikováno v:
Molecular Medicine, Vol 25, Iss 1, Pp 1-13 (2019)
Abstract Background The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TK
Externí odkaz:
https://doaj.org/article/123f53267db24bbf82582eb731ee98fe
Autor:
Giuseppina Conteduca, Davide Cangelosi, Simona Coco, Michela Malacarne, Chiara Baldo, Alessia Arado, Rute Pinto, Barbara Testa, Domenico A. Coviello
Publikováno v:
Life, Vol 12, Iss 7, p 988 (2022)
An increasing amount of evidence indicates the critical role of the NSD1 gene in Sotos syndrome (SoS), a rare genetic disease, and in tumors. Molecular mechanisms affected by NSD1 mutations are largely uncharacterized. In order to assess the impact o
Externí odkaz:
https://doaj.org/article/4e21a40845144d309055a35a4bcb4c1e
Autor:
Selene Ottonello, Carlo Genova, Irene Cossu, Vincenzo Fontana, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Marco Tagliamento, Angela Alama, Simona Coco, Simona Boccardo, Irene Vanni, Guido Ferlazzo, Lorenzo Moretta, Francesco Grossi, Maria Cristina Mingari, Paolo Carrega, Gabriella Pietra
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical
Externí odkaz:
https://doaj.org/article/d2bc4156441047f087b7ab4cc39af254
Autor:
Eugenia Cella, Lodovica Zullo, Silvia Marconi, Giovanni Rossi, Simona Coco, Chiara Dellepiane, Angela Alama, Leslie Rozeboom, Elisa Bennicelli, Francesca Parisi, Gianluca Sacco, Giulia Barletta, Linda Zinoli, Marco Tagliamento, Paolo Pronzato, Carlo Genova
Publikováno v:
Expert Opinion on Biological Therapy. 22:1259-1273
In recent years, immunotherapy has become a pillar in the treatment of advanced, non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed death ligand 1 (PD-L1) expression is currently the only factor used to predict response to immunothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d35ae40537c881240094ca39b6e23a90
https://doi.org/10.1080/14712598.2022.2116273
https://doi.org/10.1080/14712598.2022.2116273